Best AI Tools for Regulatory Decision Evidence Review (2026)

A regulatory decision evidence review is not just a summary of an approval letter or a pivotal trial. The real task is to reconstruct what evidence the regulator had, what each evidence layer could establish, how uncertainty was handled, which regulatory pathway was used, and what evidence still had to be generated after authorization.

This guide compares five tools that can support different parts of that workflow: Noah AI, Cortellis Regulatory Intelligence, AlphaSense, Elicit, and Scite.

For the real case, we tested Noah AI on Qalsody (tofersen) for SOD1-associated amyotrophic lateral sclerosis, comparing the U.S. FDA accelerated approval pathway with the European Union authorization under exceptional circumstances.

These are distinct legal and evidentiary pathways, not different conclusions reached under the same approval framework.

The FDA granted accelerated approval based on a reduction in plasma neurofilament light chain (NfL), considered reasonably likely to predict clinical benefit. The EU granted marketing authorisation under exceptional circumstances following a benefit–risk assessment in a rare disease for which comprehensive clinical data could not reasonably be obtained.

This comparison therefore examines the evidence package, the regulatory reasoning, the remaining uncertainty, and the specific post-authorisation obligations under each framework.

Testing note: We tested Noah AI directly. Other tools are described based on their documented workflows and typical regulatory or research use cases.

1. What Is Regulatory Decision Evidence Review?

A regulatory decision evidence review asks a different question from a standard clinical evidence review:

What did the evidence establish, what did it fail to establish, and how did regulators use that evidence to reach an authorization decision?

A strong review usually separates direct randomized clinical evidence, biomarker or surrogate-endpoint evidence, pharmacodynamic evidence, supportive follow-up, safety, rare-disease context, regulatory pathway, residual uncertainty, and post-approval evidence obligations.

2. Regulatory Decision Review vs Clinical Trial Review

Clinical trial review	Regulatory decision review
What did the trial show?	How did the regulator interpret the total evidence package?
Focuses on design, endpoints, effect estimates, confidence intervals, and safety	Adds biomarker role, regulatory pathway, unmet need, post-approval obligations, and residual uncertainty
May end with a trial-level interpretation	Ends with a decision-level evidence map

3. Best AI Tools for Regulatory Decision Evidence Review

Noah AI

Directly tested

Noah AI is useful when the review needs to connect regulatory documents with clinical evidence, biomarker interpretation, safety, evidence hierarchy, and unresolved questions. In the Qalsody case, the most useful outputs were the FDA-versus-EMA interpretation table and an evidence hierarchy showing exactly what each evidence component supported—and what it did not establish.

Noah AI can be used for free, includes free credits, and requires no credit card to get started.

Explore Noah AI Agent →

Cortellis Regulatory Intelligence

Cortellis Regulatory Intelligence is purpose-built for global regulatory intelligence. It is useful for searching official regulatory documents, reviewing requirements across markets, comparing document versions, and obtaining referenced summaries from regulator-focused content.

AlphaSense

AlphaSense is useful when regulatory review needs broader life-sciences context. Its regulatory content can be analyzed alongside clinical-trial records, drug approvals, safety alerts, company disclosures, and market intelligence.

Elicit

Elicit is better suited to the scientific-evidence layer. It can help retrieve, screen, extract, and synthesize the underlying clinical literature and trial records used to contextualize a regulatory package.

Scite

Scite is useful for claim-level evidence checking. Smart Citations show whether later literature supports, contrasts, or merely mentions a publication, helping researchers evaluate how pivotal claims are treated after publication.

4. Real Case: Qalsody (Tofersen) in SOD1-ALS

Qalsody is a useful case because the regulatory decision cannot be reduced to "the pivotal trial was positive" or "the pivotal trial was negative." The evidence package included an unsuccessful primary clinical endpoint, biomarker and pharmacodynamic effects, supportive longer-term evidence, safety findings, rare-disease context, and different regulatory pathways in the U.S. and EU.

5. Step 1 — Keep the Primary Clinical Endpoint Intact

The pivotal study compared tofersen with placebo in adults with SOD1-ALS. The primary clinical endpoint was change in ALSFRS-R at 28 weeks. A regulatory evidence review should preserve the fact that this primary comparison did not establish statistically significant week-28 functional benefit.

An unsuccessful primary clinical endpoint should remain unsuccessful in the evidence map. Biomarker findings should not be rewritten as if they made the primary endpoint positive.

6. Step 2 — Separate Biomarker Evidence from Direct Clinical Benefit

Plasma neurofilament light chain (NfL) played a central role in the U.S. decision. The important question is not simply whether NfL changed, but what regulatory role that change could support.

Evidence component	What it supports	What it does not establish by itself
ALSFRS-R randomized comparison	Direct test of functional clinical benefit	It did not demonstrate a statistically significant week-28 functional benefit
Plasma NfL	Biomarker evidence related to neuroaxonal injury	Definitive patient-level clinical benefit
CSF SOD1 reduction	Target engagement and pharmacodynamic activity	Improved function or survival
Open-label follow-up	Supportive longer-term patterns	The same evidentiary strength as continued randomized comparison

7. Step 3 — Understand "Reasonably Likely to Predict Clinical Benefit"

For FDA accelerated approval, a surrogate endpoint may support approval when it is considered reasonably likely to predict clinical benefit, with continued approval dependent on later verification of benefit.

Reasonably likely surrogate ≠ validated surrogate ≠ direct clinical efficacy.

This distinction explains how biomarker evidence can be regulatorily central while clinical benefit remains to be verified.

8. Step 4 — Map Pharmacodynamic Evidence Correctly

Tofersen is designed to reduce SOD1 production. A reduction in CSF SOD1 supports target engagement and pharmacodynamic activity. That is important evidence, but it answers a mechanistic question rather than proving how patients function or survive.

9. Step 5 — Interpret Supportive Follow-Up Carefully

Longer-term and open-label evidence can be informative in a rare and heterogeneous disease. But once randomized placebo-controlled follow-up is lost, interpretation becomes more vulnerable to bias, crossover effects, selection, and disease-course heterogeneity.

The appropriate label is therefore supportive, not automatically confirmatory.

10. Step 6 — Compare FDA and EMA Interpretation

The FDA and EMA assessed overlapping scientific evidence, but they applied different legal standards, regulatory reasoning, and post-authorisation requirements.

Comparison	FDA — Accelerated Approval	EU — Exceptional Circumstances
Legal pathway	Accelerated approval	Marketing authorisation under exceptional circumstances
Authorisation date	April 25, 2023	May 29, 2024
Regulatory basis	Plasma NfL reduction considered reasonably likely to predict clinical benefit	Positive benefit–risk assessment where comprehensive evidence could not reasonably be obtained because of the rarity of SOD1-ALS
Primary clinical endpoint	The randomized Week-28 ALSFRS-R comparison did not establish statistically significant clinical benefit	The same limitation in the clinical evidence remained relevant to the assessment
Biomarker evidence	Plasma NfL reduction supported the surrogate-based accelerated approval rationale	Biomarker and pharmacodynamic findings formed part of the broader evidence assessment, without applying the FDA surrogate-endpoint legal standard
Post-authorisation obligations	Confirmatory evidence to verify clinical benefit, including ATLAS	Further long-term safety and effectiveness evidence, registry follow-up, and annual reassessment

Key distinction: FDA accelerated approval is not equivalent to EU authorisation under exceptional circumstances. The agencies considered overlapping evidence, but the regulatory standards and continuing obligations differ.

The comparison should not be interpreted as evidence that one agency was more permissive or that either pathway independently established definitive clinical benefit.

Official sources:

11. Step 7 — Build an Evidence Hierarchy

The hierarchy keeps unlike evidence from being treated as interchangeable:

Randomized clinical evidence directly tests clinical outcomes.
Biomarker evidence can support a surrogate-based pathway without proving definitive clinical benefit.
CSF SOD1 reduction supports target engagement.
Open-label evidence can support continued characterization but is not equivalent to randomized verification.
Biological plausibility supports interpretation of biomarker effects but is not clinical effectiveness.
Safety evidence conditions the benefit-risk assessment and long-term monitoring.
Rarity and unmet need provide regulatory context; they are not efficacy evidence.

12. Step 8 — Keep Regulatory Context Separate from Efficacy Evidence

SOD1-ALS is rare, severe, and progressive. That context affects how regulators evaluate whether comprehensive evidence can reasonably be obtained before authorization and which regulatory pathway can apply.

Regulatory context can affect the pathway and benefit-risk framework. It does not change the underlying trial result.

13. Step 9 — Map Post-Approval Evidence Obligations

The evidence-generation process did not end when Qalsody received authorisation. However, the obligations differ because the regulatory pathways are not interchangeable.

FDA — Accelerated Approval

The FDA requires verification of clinical benefit following accelerated approval. For Qalsody, the identified postmarketing requirement includes completing the ATLAS study (233AS303), evaluating tofersen in presymptomatic adults with confirmed SOD1 mutations.

This obligation is directly connected to the requirement to verify clinical benefit after surrogate-based accelerated approval.

EU — Authorisation Under Exceptional Circumstances

The EU authorisation carries specific obligations because comprehensive efficacy and safety data could not reasonably be obtained before authorisation.

These include collecting additional long-term safety and effectiveness evidence, investigating treatment in presymptomatic individuals, following patients through a registry, and submitting registry data annually.

The EMA also conducts annual reassessment of the authorisation and its specific obligations.

Research implication: A regulatory evidence map should record the exact outstanding evidence requirements under each jurisdiction rather than merging them into a generic "confirmatory trial required" category.

The key questions are:

What uncertainty remains after authorisation?
What evidence must the sponsor continue to generate?
Which obligations are specific to the FDA pathway?
Which obligations are specific to the EU pathway?
What new evidence could materially change the benefit–risk interpretation?

14. What Makes a Regulatory Decision Review Useful?

For every evidence component, ask five questions:

What was observed?
What type of evidence is it?
What can it establish?
What can it not establish?
What role did it play in the regulatory decision?

This structure prevents fluent summaries from erasing the actual evidence hierarchy.

15. Common Mistakes

Approval = Definitive Clinical Efficacy

Authorization can occur under pathways where some aspects of clinical benefit remain unverified or where comprehensive data cannot reasonably be obtained before authorization.

Biomarker Change = Patient Benefit

A biomarker can be regulatorily important without directly demonstrating how patients feel, function, or survive.

Accelerated Approval = Traditional Approval

Accelerated approval has a specific evidentiary and postmarketing framework and should not be described as if clinical benefit has already been fully verified.

FDA Accelerated Approval = EMA Exceptional Circumstances

These are distinct regulatory pathways with different legal bases and evidence obligations.

Open-Label Follow-Up = Randomized Evidence

Longer follow-up can be supportive, but loss of randomization changes what the evidence can establish.

Advisory Committee = Final FDA Decision

Advisory committee deliberation can inform FDA but is not itself the final regulatory action.

Rarity = Efficacy Evidence

Rare-disease context can affect the feasibility of evidence generation and the regulatory pathway. It does not itself demonstrate that a drug works.

16. Which Tool Fits Which Part of the Workflow?

Research task	Useful tool	Typical role
Integrated regulatory evidence review	Noah AI	Connect regulatory documents with trial, biomarker, safety, and uncertainty evidence.
Global regulatory intelligence and precedent	Cortellis Regulatory Intelligence	Search official regulatory documents, compare markets, summarize requirements, and inspect regulatory precedent.
Regulatory + corporate intelligence context	AlphaSense	Monitor approvals, regulatory filings, trial developments, company disclosures, and market context.
Scientific evidence extraction	Elicit	Search, screen, extract, and synthesize the study literature behind the regulatory package.
Claim-level citation context	Scite	See whether pivotal scientific claims are supported, contrasted, or simply mentioned in later literature.

18. FAQ

What is regulatory decision evidence review?

It is a structured review of the scientific and regulatory evidence behind an authorization decision, including direct clinical evidence, biomarkers, safety, regulatory context, the approval pathway, unresolved uncertainty, and post-approval obligations.

Can AI explain why the FDA or EMA approved a drug?

AI can help retrieve and organize official documents and reconstruct documented reasoning. It should not speculate about agency motives beyond what the regulatory record supports.

Does regulatory approval prove clinical benefit?

Not always in the same way. The evidentiary meaning depends on the approval pathway. A surrogate-based accelerated approval, for example, requires later verification of clinical benefit.

What is the difference between a biomarker and a surrogate endpoint?

A biomarker is a measurable biological characteristic. A surrogate endpoint is a biomarker or intermediate endpoint used to support conclusions about clinical benefit under a defined evidentiary framework. Not every biomarker is a validated surrogate.

Why compare FDA and EMA decisions?

Comparing them can reveal how overlapping evidence is interpreted under different regulatory frameworks. The goal is descriptive comparison, not ranking the agencies.

Why are post-approval obligations important?

They show which questions were still unresolved at authorization and what evidence regulators expect to verify benefit, characterize long-term safety, or reduce uncertainty.

19. Final Takeaway

A regulatory decision is built from the totality of evidence—but not every piece of evidence carries the same regulatory weight.

The Qalsody case shows why regulatory decision review must preserve evidence hierarchy. The randomized clinical endpoint did not establish significant week-28 functional benefit. Plasma NfL nevertheless played a central role in the FDA accelerated approval rationale. CSF SOD1 reduction supported target engagement. Longer-term follow-up added supportive but nonconfirmatory evidence. Rare-disease context affected the regulatory framework without becoming efficacy evidence itself.

The most useful AI workflow therefore does not simply summarize the approval. It shows what each piece of evidence established, what it did not establish, how the regulator used it, and what uncertainty remains to be resolved.

Reconstruct Regulatory Decision Evidence with Noah AI

Use Noah AI to reconstruct the evidence package, regulatory reasoning, remaining uncertainty, and post-approval obligations behind drug authorisation decisions.

Compare clinical endpoints, surrogate biomarkers, pharmacodynamic evidence, regulatory pathways, and outstanding evidence requirements while keeping FDA and EMA frameworks distinct.

Free to use · Free credits included · No credit card required

Review Regulatory Decision Evidence with Noah AI →